190 related articles for article (PubMed ID: 20638838)
1. FGFR4 transmembrane domain polymorphism and cancer risk: a meta-analysis including 8555 subjects.
Xu W; Li Y; Wang X; Chen B; Wang Y; Liu S; Xu J; Zhao W; Wu J
Eur J Cancer; 2010 Dec; 46(18):3332-8. PubMed ID: 20638838
[TBL] [Abstract][Full Text] [Related]
2. Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer prognostic factor.
Frullanti E; Berking C; Harbeck N; Jézéquel P; Haugen A; Mawrin C; Parise O; Sasaki H; Tsuchiya N; Dragani TA
Eur J Cancer Prev; 2011 Jul; 20(4):340-7. PubMed ID: 21412156
[TBL] [Abstract][Full Text] [Related]
3. The fibroblast growth factor receptor-4 Arg388 allele is associated with gastric cancer progression.
Ye Y; Shi Y; Zhou Y; Du C; Wang C; Zhan H; Zheng B; Cao X; Sun MH; Fu H
Ann Surg Oncol; 2010 Dec; 17(12):3354-61. PubMed ID: 20844967
[TBL] [Abstract][Full Text] [Related]
4. Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients.
Spinola M; Leoni V; Pignatiello C; Conti B; Ravagnani F; Pastorino U; Dragani TA
J Clin Oncol; 2005 Oct; 23(29):7307-11. PubMed ID: 16061909
[TBL] [Abstract][Full Text] [Related]
5. FGFR4 Gly388Arg polymorphism and prostate cancer risk in Scottish men.
Ho CK; Anwar S; Nanda J; Habib FK
Prostate Cancer Prostatic Dis; 2010 Mar; 13(1):94-6. PubMed ID: 19918264
[TBL] [Abstract][Full Text] [Related]
6. MTHFR C677T polymorphism associated with breast cancer susceptibility: a meta-analysis involving 15,260 cases and 20,411 controls.
Zhang J; Qiu LX; Wang ZH; Wu XH; Liu XJ; Wang BY; Hu XC
Breast Cancer Res Treat; 2010 Sep; 123(2):549-55. PubMed ID: 20143151
[TBL] [Abstract][Full Text] [Related]
7. Association between fibroblast growth factor receptor-4 gene polymorphism and risk of prostate cancer: a meta-analysis.
Liwei L; Chunyu L; Jie L; Ruifa H
Urol Int; 2011; 87(2):159-64. PubMed ID: 21625079
[TBL] [Abstract][Full Text] [Related]
8. Polymorphism of XRCC1 (at codon 399) and susceptibility to breast cancer, a meta-analysis of the literatures.
Saadat M; Ansari-Lari M
Breast Cancer Res Treat; 2009 May; 115(1):137-44. PubMed ID: 18481169
[TBL] [Abstract][Full Text] [Related]
9. SRD5A2 V89L polymorphism and prostate cancer risk: a meta-analysis.
Wang C; Tao W; Chen Q; Hu H; Wen XY; Han R
Prostate; 2010 Feb; 70(2):170-8. PubMed ID: 19760631
[TBL] [Abstract][Full Text] [Related]
10. Association between mitogen-activated protein kinase kinase kinase 1 rs889312 polymorphism and breast cancer risk: evidence from 59,977 subjects.
Lu PH; Yang J; Li C; Wei MX; Shen W; Shi LP; Jiang ZY; Zhou N; Tao GQ
Breast Cancer Res Treat; 2011 Apr; 126(3):663-70. PubMed ID: 20809358
[TBL] [Abstract][Full Text] [Related]
11. The association of SULT1A1 codon 213 polymorphism and breast cancer susceptibility: meta-analysis from 16 studies involving 23,445 subjects.
Sun Y; Zang Z; Xu X; Zhang Z; Zhong L; Zan W; Zhao Y; Sun L
Breast Cancer Res Treat; 2011 Jan; 125(1):215-9. PubMed ID: 20505990
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of association between matrix metalloproteinases 2, 7 and 9 promoter polymorphisms and cancer risk.
Peng B; Cao L; Ma X; Wang W; Wang D; Yu L
Mutagenesis; 2010 Jul; 25(4):371-9. PubMed ID: 20360147
[TBL] [Abstract][Full Text] [Related]
13. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.
Thussbas C; Nahrig J; Streit S; Bange J; Kriner M; Kates R; Ulm K; Kiechle M; Hoefler H; Ullrich A; Harbeck N
J Clin Oncol; 2006 Aug; 24(23):3747-55. PubMed ID: 16822847
[TBL] [Abstract][Full Text] [Related]
14. IGFBP3 A-202C polymorphism and breast cancer susceptibility: a meta-analysis involving 33,557 cases and 45,254 controls.
Qiu LX; Yao L; Yuan H; Mao C; Chen B; Zhan P; Xue K; Zhang J; Hu XC
Breast Cancer Res Treat; 2010 Aug; 122(3):867-71. PubMed ID: 20084546
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population.
Ma Z; Tsuchiya N; Yuasa T; Inoue T; Kumazawa T; Narita S; Horikawa Y; Tsuruta H; Obara T; Saito M; Satoh S; Ogawa O; Habuchi T
Int J Cancer; 2008 Dec; 123(11):2574-9. PubMed ID: 18756523
[TBL] [Abstract][Full Text] [Related]
16. Functional FGFR4 Gly388Arg polymorphism contributes to cancer susceptibility: Evidence from meta-analysis.
Xiong SW; Ma J; Feng F; Fu W; Shu SR; Ma T; Wu C; Liu GC; Zhu J
Oncotarget; 2017 Apr; 8(15):25300-25309. PubMed ID: 28445975
[TBL] [Abstract][Full Text] [Related]
17. Intron 3 16 bp duplication polymorphism of TP53 contributes to cancer susceptibility: a meta-analysis.
Hu Z; Li X; Qu X; He Y; Ring BZ; Song E; Su L
Carcinogenesis; 2010 Apr; 31(4):643-7. PubMed ID: 20089604
[TBL] [Abstract][Full Text] [Related]
18. BRCA2 N372H polymorphism and breast cancer susceptibility: a meta-analysis involving 44,903 subjects.
Qiu LX; Yao L; Xue K; Zhang J; Mao C; Chen B; Zhan P; Yuan H; Hu XC
Breast Cancer Res Treat; 2010 Sep; 123(2):487-90. PubMed ID: 20135345
[TBL] [Abstract][Full Text] [Related]
19. XPD Lys751Gln polymorphism and breast cancer susceptibility: a meta-analysis involving 28,709 subjects.
Qiu LX; Yao L; Zhang J; Zhu XD; Zhao XM; Xue K; Mao C; Chen B; Zhan P; Yuan H; Hu XC
Breast Cancer Res Treat; 2010 Nov; 124(1):229-35. PubMed ID: 20204500
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D receptor gene polymorphisms and risk of prostate cancer: a meta-analysis.
Ntais C; Polycarpou A; Ioannidis JP
Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1395-402. PubMed ID: 14693728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
